It is good news that the FDA has approved ALK's ragweed allergy tablet for use in children – though it won't cause a huge increase in short term sales, says Sydbank senior analyst Søren Løntoft Hansen.
Allergy company ALK has received the green light from the FDA to expand the use of its ragweed allergy tablet to include children. The approval is "significant" on the US market, where ALK has yet to make its big breakthrough.
Gilead Sciences has got a green light from the US Food and Drug Administration to use the drug Trodelvy for treating metastatic urothelial cancer. This is the second approval in a short time, as Trodelvy was recently approved for treating breast cancer.
The fact that many countries around the world are pausing the vaccine from Astrazeneca has no financial consequences for the pharmaceutical giant, according to the country director of Denmark and Norway. However, he does not rule out that the vaccine might suddenly be turned into a lucrative business.
Genmab CEO Jan van de Winkel is not keen on commenting on the possibility of a settlement in the dispute between Genmab and partner Janssen concerning the distribution of earnings from the cancer drug Darzalex, according to Danish newspaper Børsen.
The statutory pension fund ATP, which holds a portion of Genmab's shares, is particularly critical of the variable part of Genmab's salary packages for the executive team and board of directors. However the proposed changes to the salaries were accepted without further issue.
In collaboration with Zealand Pharma, Boehringer Ingelheim is advancing to stage II trials with the drug candidate BI 456906 which is currently being tested as a treatment for type II diabetes. Now, the drug will prove its worth as a treatment for the fatty liver disease NASH and obesity.
Even though Rexulti did not deliver quick results in phase III against Alzheimer's disease, Lundbeck's Head of R&D Johan Luthman still sees plenty of potential in the trial which is now set to be concluded in the new year.
The rest of 2021 has to run perfectly for Orphazyme, according to portfolio manager, following the pharmaceutical firm's recent and disappointing study with main candidate arimoclomol for the muscle wasting disease IBM.
The newly founded spinout company Vectivbio, which Novo Ventures has invested millions of kroner in, has announced that it is getting listed in the US with the goal of fetching USD 127.5m for developing a treatment for short bowel syndrome, which Zealand Pharma is also banking on.
Christophe Bourdon, who has just taken on the role of CEO at Orphazyme, wants to work on reestablishing the confidence in the company, which suffered greatly following the firm's recent clinical failure.
Analyst estimates that Zealand Pharma's recently approved rescue pen Zegalogue can generate billion-kroner income for the Danish biotech company, which is getting ready to take the treatment to market.
Much can be learned from Kesimpta's path from disappointing cancer treatment to promising sclerosis medication, according to Genmab's CEO Jan van de Winkel – even if this has led to some frustration along the way.